Breaking News, Collaborations & Alliances

Asimov and RevOpsis Partner to Advance Ophthalmic Therapeutics

Sign licensing agreement for high titer multispecific-expressing cell line.

Author Image

By: Charlie Sternberg

Associate Editor

Asimov, a synthetic biology company advancing the design and manufacture of therapeutics, has entered a licensing agreement for its CHO Edge System with RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation of multispecific biologics in ophthalmic therapies. This agreement follows a successful cell line development campaign with Asimov’s CHO Edge System for the lead RevOpsis asset, RO-104.   Under the terms of the agreement, RevOpsis will integrate the CHO ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters